Corbus Pharmaceuticals Announces Proposed Public Offering

Rhea-AI Summary

Corbus Pharmaceuticals (Nasdaq: CRBP) announced on Oct 30, 2025 a proposed underwritten public offering of its common stock and, for certain investors, pre-funded warrants to purchase common stock. All securities will be sold by Corbus, and the offering is subject to market conditions with no assurance of completion, size, or terms.

Corbus said it intends to use net proceeds to fund clinical development of its pipeline and for working capital and general corporate purposes. Jefferies and Piper Sandler are joint book-running managers, and underwriters may receive a 30-day option to buy up to an additional 15% of the shares. A registration statement became effective on Mar 20, 2024.

Insights

Capital markets strategist

Planned registered offering signals an immediate capital raise to fund development and working capital.

The company announced a proposed underwritten public offering of its common stock and conditional pre-funded warrants, with the firm granting underwriters a 30-day option to purchase up to an additional 15% of the shares. The offering is to be sold by the company and is explicitly subject to market conditions and final terms to be set in a prospectus supplement.

Primary dependencies and risks include market receptivity, final offering size and pricing, and the timing of the prospectus filing; none of these are fixed in the announcement. Watch for the filed preliminary prospectus supplement that will disclose the exact share count, price range, and intended use of proceeds; timing is near-term given the press release dated Oct. 30, 2025.

Corporate finance analyst

Offering aims to fund clinical programs and general corporate needs but leaves size and terms unspecified.

The company states net proceeds will fund clinical development and provide working capital. The securities will be sold by the company, and a previously effective registration statement from March 20, 2024 supports the offering; joint book-running managers are named as Jefferies LLC and Piper Sandler & Co.

Key near-term items to monitor are the preliminary prospectus supplement for concrete figures and the underwriters' exercise of the 15% option within the stated 30-day window; the announcement contains no state blue-sky qualifications and cautions that completion depends on market conditions, so expect updates on filing details and pricing imminently.

NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Corbus intends to use the net proceeds of the proposed underwritten offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes.

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. Corbus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on March 20, 2024. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of a prospectus, copies of which may be obtained, when available, at the SEC’s website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Corbus’ expectations regarding the completion, timing and size of its public offering and the anticipated use of proceeds therefrom. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Corbus’ business and finances in general, including the risks and uncertainties in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering that will be filed with the SEC and the Company’s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. There can be no assurances that we will be able to complete the proposed offering on the anticipated terms, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corbus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Corbus Pharmaceuticals Contacts: 

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

FAQ

What did Corbus (CRBP) announce on Oct 30, 2025 about a stock offering?

Corbus announced a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants, with all securities to be sold by the company.

How does Corbus (CRBP) plan to use the proceeds from the Oct 30, 2025 offering?

Corbus intends to use net proceeds to fund clinical development of its pipeline and for working capital and other general corporate purposes.

Who are the underwriters for Corbus (CRBP) proposed offering announced Oct 30, 2025?

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

What underwriting option was disclosed in Corbus (CRBP) Oct 30, 2025 press release?

Corbus intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the public offering.

Is the Corbus (CRBP) offering announced Oct 30, 2025 guaranteed to proceed?

No; the offering is subject to market conditions and there is no assurance as to whether or when it will be completed or its final size or terms.